Business Context and Reporting Period
This Form 8-K filing by Personalis, Inc. (PSNL) reports on corporate governance and executive leadership changes effective March 2, 2023. The filing details the appointment of new principal officers and the execution of amended employment and severance agreements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment terms.
Material Changes
The primary material change is the restructuring of the executive leadership team:
- Christopher Hall appointed as Chief Executive Officer (CEO) and added to the Board of Directors as a Class II director.
- Aaron Tachibana appointed as Chief Operating Officer (COO) while retaining his role as Chief Financial Officer (CFO).
- Richard Chen promoted to Executive Vice President, R&D, while retaining his role as Chief Medical Officer.
Compensation, Guidance, and Risks
The filing outlines specific compensation packages and severance terms for the newly appointed officers. No forward-looking guidance, management commentary on business outlook, or discussion of general business risks is provided in this document.
Executive Compensation Summary
| Officer | Base Salary | Target Bonus | Stock Option Grant | Vesting Schedule |
|---|---|---|---|---|
| Aaron Tachibana (COO/CFO) | $515,000 | 60% of base | 450,000 shares | 36 months |
| Christopher Hall (CEO) | $550,000 | 80% of base | 400,000 shares | 36 months |
| Richard Chen (EVP R&D) | $500,000 | 60% of base | 250,000 shares | 36 months |
Severance Provisions
- Termination without Cause/Good Reason: Tachibana and Chen are eligible for 9 months of base salary plus COBRA; Hall is eligible for 12 months of base salary plus COBRA.
- Change in Control: All three officers are eligible for 12 months of base salary, target bonus, COBRA, and full acceleration of unvested equity awards if separation occurs within 12 months of a change in control.
Investor Verification Checklist
- Verify the closing stock price on March 15, 2023, to determine the exercise price for the new stock option grants.
- Review the full text of the employment and severance agreements (Exhibits 10.1 through 10.6) for specific definitions of "cause," "good reason," and "change in control."
- Confirm the impact of these leadership changes on the company's strategic direction by reviewing subsequent press releases or earnings calls.
- Assess the dilution impact of the 1.1 million total new stock options granted to the executive team.